Scientific summary Background
Heart failure (HF) is a debilitating condition. Surgery and devices are costly. For the NHS to allocate and deliver its services, relative costs and benefits of various treatments need to be estimated. We aimed to investigate ventricular assist devices (VADs) used as a bridge to transplant (BTT) and as an alternative to transplant (ATT) for patients in the UK for patients with advanced HF who are eligible for heart transplant (HT). There are a number of newer devices and it is important to know the comparative cost-effectiveness of devices used in this way, relative to medical management (MM).
We know that historically HT has offered the best treatment option in terms of both length and quality of life (QoL) for these patients. However, HT is dependent on supply of donor hearts, whose availability appears to be diminishing while the design of VADs has been improving.
Research questions
In patients aged ≥ 16 years with advanced HF who are eligible for HT: 
Inclusion criteria

Study design
l Studies with control groups [i.e. randomised controlled trials (RCTs), cohort studies, case-control studies], systematic reviews of studies with control groups. l Case series were included if they included over 50 participants and were published in the last 5 years.
Population
l Participants (aged > 16 years) with advanced HF and considered suitable for receipt of a left ventricular assist device (LVAD), right ventricular assist device (RVAD) or biventricular assist device (BiVAD) as BTT or as potential long-term alternative to HT. Studies which reported BTT and destination therapy (DT) participants, but did not distinguish outcomes according to therapy, were included for purposes of completeness of information, but outcomes data were not included in the main text. 
Review methods
Quality criteria were applied independently by two reviewers using a recognised quality assessment checklist; disagreements were resolved by independent assessment by a third reviewer.
Methods of analysis/synthesis
Data were tabulated and discussed in a narrative review based on the type of VAD.
Cost-effectiveness review methods
A systematic review of cost-effectiveness publications of VADs was undertaken using the same search strategies and methods as the clinical effectiveness review but including relevant costs search terms. Data from the UK Blood and Transplant Database (BTDB) were obtained from the UK Transplant Registry maintained on behalf of the UK transplant community. The data set has been maintained as part of the National Specialist Commissioning Advisory Group (NSCAG) funded VAD programme and data are included from May 2002 to December 2011. The data are collected for patients from six UK centres (listed below) which are responsible for carrying out VAD implantation surgery: 
Results
Clinical effectiveness results
We identified 40 relevant publications. There were no randomised studies in our defined patient group (eligible for HT). The majority of included publications described single-arm prospective or retrospective case studies. No publication compared BTT outcomes with those for concurrent controls involving MM or best supportive care. Observations were often based on small numbers of patients from single centres who were participating in multicentre clinical studies. Overall, the study designs were not strong: studies were likely to be only moderately representative of underlying populations, there were no randomised trials and blinding of outcomes assessors was weak. ); one-quarter of patients, 25.2% (95% CI 17.4% to 35.1%), were estimated to have diabetes mellitus; study participants had very severe HF with 83.5% (95% CI 78.0% to 87.9%) overall rated as NYHA class IV; most participants were supported with inotrope medication, 80.8% (95% CI 50.9% to 94.5%), and had low mean systolic blood pressure (BP), 97.3 mmHg (95% CI 92.8 to 101.7 mmHg).
By 12 months patients had suffered a variety of serious complications. Studies reported the following wide ranges for adverse events: 4-27% bleeding requiring transfusion; 1.5-40% stroke; 3.3-48% infection; 1-14% device failure; 3-30% HF; 11-32% reoperation; and 3-53% renal failure. Publications reported results from a variety of QoL and functional status measures. Statistically significant improvements in QoL and functional status were reported in studies of two devices [HeartMate II ® (Thoratec Inc., CA, USA) and HeartWare ® (HeartWare Inc., Framingham, MA, USA)]. There is still insufficient published evidence on second-and third-generation devices to draw robust conclusions about survival, adverse events and QoL for patients receiving these devices compared with MM without VAD.
UK Blood and Transplant Database individual patient data analysis
Using the UK BTDB, which has a large sample size reflecting UK practice, we identified 235 patients who had received a VAD. These patients were also mostly male, 80.4% (95% CI 74.77% to 84.99%), but were somewhat younger, mean age 44 years (95% CI 42.72 to 45.28 years), with a less severe NYHA class rating, class IV 58.1% (95% CI 39.07% to 75.45%), than in the published literature and were also more likely to be white, 89.7% (95% CI 81.80% to 90.86%), as compared with patients in published literature studies. Median survival with a VAD in this population was 32.1 months.
Just over three-quarters of these patients had been treated with inotropes prior to surgery, as compared with published BTT registry studies, which give slightly higher rates at 80%. In contrast, only just over 20% (307) of the 1496 UK BTDB MM patients were categorised as using inotrope treatment, supporting the use of the 'inotrope' subcategory of BTDB patients for the base-case (MM) comparator group in the economic model. Modelling of survival for these BTDB inotrope MM patients yielded a median survival of 9.1 months. HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 53 (SCIENTIFIC SUMMARY) v Cost-effectiveness results l For research question 1, VADs used as BTT had higher mean costs in comparison with medically managed patients with higher survival and QoL benefits. This was the case for all the various scenarios examined for BTT patients and for all time horizons considered [3 years, 10 years and 50 years (lifetime)]. Probabilistic and deterministic results were confirmatory. l In the base-case scenario for VAD patients compared with medically managed patients, the lifetime ICER was £55,173/QALY in the deterministic model. For a shorter time horizons of 3 years and 10 years the ICERs were £122,730/QALY and £68,088/QALY respectively. The base-case lifetime probabilistic ICER was £53,527/QALY. l For research question 2, patient mean costs were lower for VADs used as ATT as compared with VADs used as BTT, but mean benefits were also reduced. Over the 3-year, 10-year and lifetime study horizons the ICERs (cost/QALY) were £353,467, £31,685 and £20,637 respectively (these ICERs are distributed in the 'south-west' quadrant of the cost-effectiveness plane); both costs and benefits for the VAD as ATT group were reduced relative to those for VAD as BTT. Probabilistic analysis confirmed these findings.
Conclusions and recommendations for future research
Our findings of a relative lack of cost-effectiveness for VADs as BTT relative to MM given standard levels of willingness to pay for a QALY in the NHS concur with those of other researchers. However, it is clear that devices are changing and improving and in the base-case analysis, cost-effectiveness over a lifetime horizon approaches that for interventions adopted by the NHS as end of life treatments. The cost of VADs would need to be reduced by 15% in order to bring the base-case lifetime time horizon ICER to £50,000 per QALY and by 76% to bring the ICER to £30,000 per QALY.
Future research
No RCT has been published allowing comparison of BTT with VADs versus MM. For ethical reasons a RCT offering equal probability of HT for each group would not be feasible. Therefore, attention should be directed towards:
1. How any future evaluations of second-or third-generation VADs might be conducted. Future studies should fully assess costs, long-term patient survival, QoL, functional ability and adverse events, so these may be incorporated into economic evaluation. 2. Agreement on outcome measures across future studies, in particular length of follow-up, time points for data collection, agreed QoL and functional ability measures. 3. Consideration of support for the UK BTBD so as to ensure that full and accurate records of all patients are kept, and that regular analyses and comparative assessments of performance with other international centres are undertaken. 4. Consideration of extending the UK BTDB data collection process so as to include QoL data [e.g. using the European quality of life-5 dimensions (EQ-5D)], and to include resource-use data in order to facilitate future cost-effectiveness evaluation. 5. Development of guidance in the use of VADs as technology and management continue to change.
It will be important to monitor and update this assessment regularly.
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